CFG Pharma: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
CFG Pharma
Largest movements
- Intangible fixed assets -€10,000
down €10,000 (-16.4%), from €60,819 to €50,819
- Cash -€4,205
down €4,205 (-97.7%), from €4,305 to €99
mainly Net result for the year (-€28,517)
- Profit (loss) carried forward -€28,517
down €28,517 (-8.7%), from -€328,820 to -€357,337
- Accrued charges and deferred income +€8,642
up €8,642 (+207%), from €4,185 to €12,826
- Other debts +€5,000
up €5,000 (+2.1%), from €240,000 to €245,000
- Gross operating margin +€4,165
up €4,165 (+79.2%), from -€5,261 to -€1,097
- Financial charges +€886
up €886 (+5.5%), from €16,138 to €17,024
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €65,574 | €50,919 | -€14,656 | -22.3% |
| Fixed assets | 21/28 | €60,819 | €50,819 | -€10,000 | -16.4% |
| Intangible fixed assets | 21 | €60,819 | €50,819 | -€10,000 | -16.4% |
| Current assets | 29/58 | €4,755 | €99 | -€4,656 | -97.9% |
| Amounts receivable within one year | 40/41 | €450 | - | -€450 | |
| Other amounts receivable | 41 | €450 | - | -€450 | |
| Cash at bank and in hand | 54/58 | €4,305 | €99 | -€4,205 | -97.7% |
| Total equity and liabilities | 10/49 | €65,574 | €50,919 | -€14,656 | -22.3% |
| Equity | 10/15 | -€178,820 | -€207,337 | -€28,517 | -15.9% |
| Contributions | 10/11 | €150,000 | €150,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€328,820 | -€357,337 | -€28,517 | -8.7% |
| Amounts payable | 17/49 | €244,395 | €258,256 | +€13,861 | +5.7% |
| Amounts payable within one year | 42/48 | €240,210 | €245,430 | +€5,220 | +2.2% |
| Trade debts | 44 | €210 | €430 | +€220 | +105% |
| Suppliers | 440/4 | €210 | €430 | +€220 | +105% |
| Other amounts payable | 47/48 | €240,000 | €245,000 | +€5,000 | +2.1% |
| Accrued charges and deferred income | 492/3 | €4,185 | €12,826 | +€8,642 | +207% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €10,000 | €10,000 | = | 0.0% |
| Other operating charges | 640/8 | €387 | €400 | +€12 | +3.2% |
| Gross operating margin | 9900 | -€5,261 | -€1,097 | +€4,165 | +79.2% |
| Operating profit (loss) | 9901 | -€15,649 | -€11,496 | +€4,152 | +26.5% |
| Financial income | 75/76B | - | €3 | +€3 | |
| Recurring financial income | 75 | - | €3 | +€3 | |
| Financial charges | 65/66B | €16,138 | €17,024 | +€886 | +5.5% |
| Recurring financial charges | 65 | €16,138 | €17,024 | +€886 | +5.5% |
| Profit (loss) for the period before taxes | 9903 | -€31,786 | -€28,517 | +€3,269 | +10.3% |
| Profit (loss) for the period | 9904 | -€31,786 | -€28,517 | +€3,269 | +10.3% |
| Profit (loss) for the period to be appropriated | 9905 | -€31,786 | -€28,517 | +€3,269 | +10.3% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 19 October 2026 via checked.be.